NCT03685708View on ClinicalTrials.gov

HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I)

PHASE2CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

December 7, 2018

Primary Completion Date

December 16, 2020

Study Completion Date

December 16, 2020

Conditions
HepatitisSafety and Tolerability
Interventions
BIOLOGICAL

HEPLISAV-B

HEPLISAV-B (Hepatitis B Vaccine \[Recombinant \], adjuvanted) vaccine - A series of 2 doses (0.5 ml each) will be given on a 0- and 3- month schedule via intramuscular injection.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH

NCT03685708 - HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I) | Biotech Hunter | Biotech Hunter